# Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

> **NCT01151215** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 482 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** AZD8931
- **DRUG:** anastrozole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01151215
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 482 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151215, "Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01151215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*